Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 151

1.

Genetic determinants of clopidogrel responsiveness in Koreans treated with drug-eluting stents.

Park JJ, Park KW, Kang J, Jeon KH, Kang SH, Ahn HS, Han JK, Koh JS, Lee SE, Yang HM, Lee HY, Kang HJ, Koo BK, Oh BH, Park YB, Kim HS.

Int J Cardiol. 2013 Feb 10;163(1):79-86. doi: 10.1016/j.ijcard.2012.09.075. Epub 2012 Dec 20.

PMID:
23260377
2.

Cilostazol attenuates on-treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: a genetic substudy of the CILON-T randomised controlled trial.

Park KW, Park JJ, Lee SP, Oh IY, Suh JW, Yang HM, Lee HY, Kang HJ, Cho YS, Koo BK, Youn TJ, Chae IH, Choi DJ, Oh BH, Park YB, Kim HS.

Heart. 2011 Apr;97(8):641-7. doi: 10.1136/hrt.2010.216499. Epub 2011 Feb 22.

PMID:
21345843
3.

Paraoxonase-1 activity affects the clopidogrel response in CYP2C19 loss-of-function carriers.

Nishio R, Shinke T, Otake H, Nakagawa M, Inoue T, Hariki H, Osue T, Taniguchi Y, Iwasaki M, Hiranuma N, Konishi A, Kinutani H, Kuroda M, Hirata K.

Thromb Res. 2013 Nov;132(5):558-64. doi: 10.1016/j.thromres.2013.09.008. Epub 2013 Sep 13.

PMID:
24080149
4.

Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes.

Nagashima Z, Tsukahara K, Morita S, Endo T, Sugano T, Hibi K, Himeno H, Fukui K, Umemura S, Kimura K.

J Cardiol. 2013 Sep;62(3):158-64. doi: 10.1016/j.jjcc.2013.03.006. Epub 2013 Jul 22.

5.

Effect of the CYP2C19 2 and 3 genotypes, ABCB1 C3435T and PON1 Q192R alleles on the pharmacodynamics and adverse clinical events of clopidogrel in Chinese people after percutaneous coronary intervention.

Tang XF, Wang J, Zhang JH, Meng XM, Xu B, Qiao SB, Wu YJ, Chen J, Wu Y, Chen JL, Gao RL, Yuan JQ, Yang YJ.

Eur J Clin Pharmacol. 2013 May;69(5):1103-12. doi: 10.1007/s00228-012-1446-8. Epub 2012 Nov 14.

PMID:
23150151
6.

Effect of CYP2C19 Polymorphisms on the Platelet Response to Clopidogrel and Influence on the Effect of High Versus Standard Dose Clopidogrel in Carotid Artery Stenting.

González A, Moniche F, Cayuela A, García-Lozano JR, Torrecillas F, Escudero-Martínez I, Gonzalez-Marcos JR, Mayol A, Montaner J.

Eur J Vasc Endovasc Surg. 2016 Feb;51(2):175-86. doi: 10.1016/j.ejvs.2015.09.020. Epub 2015 Oct 31.

7.

Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation.

Harmsze A, van Werkum JW, Bouman HJ, Ruven HJ, Breet NJ, Ten Berg JM, Hackeng CM, Tjoeng MM, Klungel OH, de Boer A, Deneer VH.

Pharmacogenet Genomics. 2010 Jan;20(1):18-25. doi: 10.1097/FPC.0b013e328333dafe.

PMID:
19934793
8.

CYP3A4 genetic status may be associated with increased vulnerability to the inhibitory effect of calcium-channel blockers on clopidogrel.

Park JJ, Park KW, Kang J, Jeon KH, Kang SH, Ahn HS, Han JK, Koh JS, Lee SE, Yang HM, Lee HY, Kang HJ, Koo BK, Oh BH, Park YB, Kim HS.

Circ J. 2013;77(5):1289-96. Epub 2013 Feb 9.

9.

Impact of CYP3A5 polymorphism on platelet reactivity at percutaneous coronary intervention and after 9 months of aspirin and clopidogrel therapy in Japanese patients with coronary artery disease.

Hokimoto S, Chitose T, Mizobe M, Akasaka T, Arima Y, Kaikita K, Iwashita S, Morita K, Miyazaki H, Oniki K, Matsui K, Nakagawa K, Ogawa H.

Eur J Clin Pharmacol. 2014 Jun;70(6):667-73. doi: 10.1007/s00228-014-1672-3. Epub 2014 Apr 26.

PMID:
24763934
10.

Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients.

Zhang L, Chen Y, Jin Y, Qu F, Li J, Ma C, Yang J, Xu B, Wang H, Li X, Li Y, Zhang Y, Lu C, Yin T.

Thromb Res. 2013 Jul;132(1):81-7. doi: 10.1016/j.thromres.2013.05.006. Epub 2013 May 29.

PMID:
23726091
11.

Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin.

Jeong YH, Tantry US, Kim IS, Koh JS, Kwon TJ, Park Y, Hwang SJ, Bliden KP, Kwak CH, Hwang JY, Gurbel PA.

Circ Cardiovasc Interv. 2011 Dec 1;4(6):585-94. doi: 10.1161/CIRCINTERVENTIONS.111.962555. Epub 2011 Nov 1.

12.

[Clopidogrel metabolism related gene polymorphisms in Chinese patients with acute coronary syndrome].

Feng GX, Liang Y, Bai Y, Chen T, Liu X, Yang YM, Wang XY, Yang YJ, Zhu J.

Zhonghua Xin Xue Guan Bing Za Zhi. 2012 Nov;40(11):908-13. Chinese.

PMID:
23363670
13.

No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting.

Sibbing D, Koch W, Massberg S, Byrne RA, Mehilli J, Schulz S, Mayer K, Bernlochner I, Schömig A, Kastrati A.

Eur Heart J. 2011 Jul;32(13):1605-13. doi: 10.1093/eurheartj/ehr155. Epub 2011 Apr 28.

PMID:
21527445
14.

The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients.

Namazi S, Kojuri J, Khalili A, Azarpira N.

Biochem Pharmacol. 2012 Apr 1;83(7):903-8. doi: 10.1016/j.bcp.2012.01.003. Epub 2012 Jan 12.

PMID:
22265638
15.

Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention.

Rideg O, Komócsi A, Magyarlaki T, Tokés-Füzesi M, Miseta A, Kovács GL, Aradi D.

Pharmacogenomics. 2011 Sep;12(9):1269-80. doi: 10.2217/pgs.11.73. Epub 2011 Aug 1.

PMID:
21806387
16.

The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention.

Hwang SJ, Jeong YH, Kim IS, Koh JS, Kang MK, Park Y, Kwak CH, Hwang JY.

Thromb Res. 2011 Jan;127(1):23-8. doi: 10.1016/j.thromres.2010.10.021.

PMID:
21075428
17.

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.

Mega JL, Close SL, Wiviott SD, Shen L, Walker JR, Simon T, Antman EM, Braunwald E, Sabatine MS.

Lancet. 2010 Oct 16;376(9749):1312-9. doi: 10.1016/S0140-6736(10)61273-1.

18.

Relationship between CYP2C19 loss-of-function polymorphism and platelet reactivities with clopidogrel treatment in Japanese patients undergoing coronary stent implantation.

Nakata T, Miyahara M, Nakatani K, Wada H, Tanigawa T, Komada F, Hoshino K, Aoki T, Nishimura Y, Tamaru S, Ito M, Nishikawa M; McLordd Group.

Circ J. 2013;77(6):1436-44. Epub 2013 Mar 8.

19.

Feasibility of a microarray-based point-of-care CYP2C19 genotyping test for predicting clopidogrel on-treatment platelet reactivity.

Chae H, Kim M, Koh YS, Hwang BH, Kang MK, Kim Y, Park HI, Chang K.

Biomed Res Int. 2013;2013:154073. doi: 10.1155/2013/154073. Epub 2013 Mar 28.

Supplemental Content

Support Center